De vooraanstaande Health Technology Assessment international (HTAi) Annual Meeting vindt in 2022 plaats in Utrecht. Dit is een internationale, hybride conferentie waar meer dan 1.000 onderzoekers, beleidsmakers, zorgverleners, instanties en patiënten/consumenten van over de hele wereld samenkomen
Would you like to get vaccinated, or tested for covid-19? Starting today, you can do this (temporarily though) at the Bestuursgebouw of the Utrecht University (Heidelberglaan 8) without an appointment. This temporary vaccination and test location at the USP is an initiative of the GGD, the UU and the HU, and will be running till further notice.
The residents of Utrecht are genuinely excited about celebrating the city’s 900th birthday together. The municipality received a large number of requests to financially support celebratory activities in the first round of applications and has already awarded grants to 34 initiators.
At the start of November, a total artificial heart was implanted in a patient with very severe heart failure for the first time in the Netherlands at UMC Utrecht. The artificial heart replaces and takes over the function of the entire heart. The innovative artificial heart improves pump function and blood supply, reducing the patient's symptoms. Implantation of the artificial heart was successful. The patient is doing well and was discharged from Intensive Care within two days.
This week, in the meadows of Utrecht Science Park, Anton Pijpers, chairman of the Executive Board of Utrecht University, dug the first shovel into the ground where more than 6,000 indigenous bushes and trees will be planted. This green strip of the university will form a new 400 meter-long ‘hedgerow’, which will contribute to the biodiversity of the area, and restore the connection with the Amelisweerd forest.
New, targeted drugs can extend the lives of children with cancer who have particular DNA changes in their tumor, a new study shows. The results offer evidence for the value of treating children based on the biology of their tumor, says co-lead researcher Jan Molenaar.
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the “Offer Shares”).
Utrecht Science Park is the beating heart of one of Europe's most competitive regions. We bring competence from business, industry and academia together in order to design and create healthier, safer and more sustainable cities for today and for subsequent generations.
Utrecht Science Park provides a vibrant, dynamic and exciting place to work, to study and to interact